Business Description
Merrimack Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
MP6N.Germany
•
MACK.USA
Description
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.97 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | -2.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 65.5 | |||||
| 3-Year EPS without NRI Growth Rate | 65.9 | |||||
| 3-Year FCF Growth Rate | 85.2 | |||||
| 3-Year Book Growth Rate | -37.9 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.54 | |||||
| 9-Day RSI | 27.04 | |||||
| 14-Day RSI | 31.18 | |||||
| 6-1 Month Momentum % | -34.69 | |||||
| 12-1 Month Momentum % | -8.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 31.85 | |||||
| Quick Ratio | 31.85 | |||||
| Cash Ratio | 30.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -11.25 | |||||
| ROA % | -10.79 | |||||
| ROIC % | -568.6 | |||||
| ROC (Joel Greenblatt) % | -1528.37 | |||||
| ROCE % | -15.05 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.52 | |||||
| Price-to-Tangible-Book | 3.49 | |||||
| EV-to-EBIT | -15.96 | |||||
| EV-to-EBITDA | -15.96 | |||||
| EV-to-FCF | -17.13 | |||||
| Price-to-Net-Current-Asset-Value | 3.52 | |||||
| Price-to-Net-Cash | 3.71 | |||||
| Earnings Yield (Greenblatt) % | -6.27 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MACK
Peter Lynch Chart
Performance
Dividend
Annualized Return %
Total Annual Return %
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -0.12 | ||
| Beta | 1.08 | ||
| Volatility % | 54.1 | ||
| 14-Day RSI | 31.18 | ||
| 14-Day ATR ($) | 0.232409 | ||
| 20-Day SMA ($) | 4.00184 | ||
| 12-1 Month Momentum % | -8.17 | ||
| 52-Week Range ($) | 3.53 - 7.41 | ||
| Shares Outstanding (Mil) | 13.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Merrimack Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Merrimack Pharmaceuticals Inc Analysis
Share your researchHeadlines
See More
No news.